PROVENGE®, activated peripheral blood derived-mononuclear cells for metastatic prostate cancer
PROVENGE® consists of autologous peripheral blood mononuclear cells, including antigen presenting cells (APCs), that have been activated during a defined culture period with a recombinant human protein, PAP-GM-CSF. PAP-GM-SCF consists of prostatic acid phosphatase (PAP), an antigen expressed in prostate cancer tissue, linked to granulocyte-macrophage colony stimulating factor (GM-CSF), an immune cell activator. The patient’s peripheral blood mononuclear cells are obtained via a standard leukapheresis procedure, approximately 3 days prior to the treatment date.
Treatment induced an immunological (IgM and IgG) response against PAP-GM-CSF and against PAP antigen. The immunological reaction to GM-CSF was transient. Survival was higher in treated patients. No effect on time to disease progression was observed and the safety profile is acceptable.
Read More
Product Information for
PROVENGE®, activated peripheral blood derived-mononuclear cells for metastatic prostate cancer
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access